Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENV-294 in Moderate-to-Severe Atopic Dermatitis
NCT07298395Phase 2Recruiting
- Sponsor
- Enveda Biosciences
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing ENV-294 Treatment Arm with Placebo Arm (2 arms). Primary endpoint: Severity and extent of atopic dermatitis at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
ENV-294
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07298395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298395.